Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Combination of antiangiogenic treatment and immune checkpoint inhibition improves antitumor immunity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These results suggest that the anticancer activity of the proposed DDS could promise to target Ang-2 supporting the immune checkpoints inhibition [89,91].”
From Targeted Nano-Drug Delivery of Colchicine against Colon Cancer Cells by Means of Mesoporous Silica Nanoparticles (2020) · cites this paper as [89]
In the citing paper
“In a study by Schmittnaegel et al., inhibition of Ang-2 together with vascular endothelial growth factor A (VEGFA) enhanced the antitumor immunity, allowing PD-1 checkpoint inhibition [89].”
From Targeted Nano-Drug Delivery of Colchicine against Colon Cancer Cells by Means of Mesoporous Silica Nanoparticles (2020) · cites this paper as [89]
In the citing paper
“We previously demonstrated that vascular normalization could increase immune cells’ infiltration into tumors, and multiple studies have confirmed these findings in several tumor models (15,17-19).”
In the citing paper
“An improved vascular network favors adaptive antitumor immunity by promoting trafficking and re-localization of tumor-infiltrating lymphocytes (TILs), leading to improved outcomes of various immunotherapies, including immune checkpoint blockade (ICB) (15-20).”
In the citing paper
“Lack of perfusion, tumoral hypoxia, and T-cell exclusion are considered significant resistance mechanisms (15,17-19).”
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · cited 3×
“9, eaak9670 (2017) 12 April 2017 may be reminiscent of findings in cancer patients receiving immune checkpoint blockade: Although the antitumoral responses can be marked and long-lasting in some cases, they typically involve only a minority of the patients (17).”
BackgroundAccessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605 · cited 1×
“Vascular endothelial growth factor A (VEGFA) is a key promoter of tumor angiogenesis (3).”
BackgroundModes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 2×
“The lack of durable antitumoral responses after VEGFA inhibition mirrors that of other targeted drugs and can be attributed, at least in part, to compensatory proangiogenic signaling, either induced or preexisting in tumors (4, 5).”
BackgroundVessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,195 · cited 1×
“ANGPT2 neutralization might exacerbate vascular co-option by cancer cells (39), and there is also evidence that genetic Angpt2 deficiencymay aggravate the progression of colorectal liver metastasis in mice (40).”
BackgroundCancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049 · cited 1×
“9, eaak9670 (2017) 12 April 2017 which may be conducive to the activation of tumor-specific CD8 CTLs, and the phagocytic activity of tumor-associated APCs, which primarily stimulate CD4 T helper functions through MHCII-mediated antigen presentation (31).”
BackgroundGabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977 · cited 2×
“For example, VEGFA can directly impair DC maturation, and neutralization of VEGFA enhances the antigen-presenting capacity of DCs in mouse tumor models (44, 45).”
BackgroundInduction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Altered macrophage differentiation and immune dysfunction in tumor development
Sica, A., & Bronte, V. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31422 · Cited by 1,238 · cited 1×
“Increasing experimental evidence has implicated myeloid cells—namely, macrophages, neutrophils, and subsets thereof—as a source of immunosuppressive cues in the tumor microenvironment (32, 33).”
BackgroundLin, E. Y., Jones, J. G., Li, P., Zhu, L., Whitney, K. D., Muller, W. J., & Pollard, J. W. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63568-7 · Cited by 1,107
Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., & Carbone, D. P. (1998) · Blood · doi:10.1182/blood.v92.11.4150 · Cited by 1,048 · cited 2×
“For example, VEGFA can directly impair DC maturation, and neutralization of VEGFA enhances the antigen-presenting capacity of DCs in mouse tumor models (44, 45).”
BackgroundTumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Motz, G. T., Santoro, S. P., Wang, L.-P., Garrabrant, T., Lastra, R. R., Hagemann, I. S., Lal, P., Feldman, M. D., Benencia, F., & Coukos, G. (2014) · Nature Medicine · doi:10.1038/nm.3541 · Cited by 1,035
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030 · cited 2×
“INTRODUCTION Tumor angiogenesis—the formation of a tumor-associated vascular network—is essential for cancer growth and progression (1, 2).”
BackgroundPalucka, A. K., & Coussens, L. M. (2016) · Cell · doi:10.1016/j.cell.2016.01.049 · Cited by 843
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9679 · Cited by 820
Wallin, J. J., Bendell, J. C., Funke, R., Sznol, M., Korski, K., Jones, S., Hernandez, G., Mier, J., He, X., Hodi, F. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12624 · Cited by 713
Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
Huang, Y., Goel, S., Duda, D. G., Fukumura, D., & Jain, R. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4354 · Cited by 669 · cited 3×
“Blocking ANGPT2 prunes immature tumor blood vessels while promoting thematuration and stabilization of the remaining vessels (6–8, 14, 29); these vascular-normalizing effects may facilitate T cell trafficking in tumors (19, 20).”
BackgroundMazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., Politi, L. S., Gentner, B., Brown, J. L., Naldini, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.005 · Cited by 639 · cited 7×
“LC06 decreased angiogenesis and delayed tumor growth in a transplanted MMTVPyMT tumor model, consistent with data obtained with a different anti-ANGPT2 antibody (6, 7).”
BackgroundResultInfluentialHarney, A. S., Arwert, E. N., Entenberg, D., Wang, Y., Guo, P., Qian, B.-Z., Oktay, M. H., Pollard, J. W., Jones, J. G., & Condeelis, J. S. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0012 · Cited by 618
Bevacizumab plus ipilimumab in patients with metastatic melanoma
Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0053 · Cited by 593 · cited 3×
“Bevacizumab plus ipilimumab also increased the proportion of circulating T cells expressing a memory phenotype, as well as the titers of serum antibodies against galectin family members (47).”
BackgroundBuckanovich, R. J., Facciabene, A., Kim, S., Benencia, F., Sasaroli, D., Balint, K., Katsaros, D., O'Brien-Jenkins, A., Gimotty, P. A., & Coukos, G. (2008) · Nature Medicine · doi:10.1038/nm1699 · Cited by 546 · cited 1×
“Furthermore, angiogenic tumor ECs express surface receptors or soluble mediators, such as endothelin B receptor, which can blunt the effector functions of T cells newly recruited to the tumor (42, 43).”
BackgroundThe parallel lives of angiogenesis and immunosuppression: cancer and other tales
Motz, G. T., & Coukos, G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3064 · Cited by 481
Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
Frentzas, S., Simoneau, E., Bridgeman, V. L., Vermeulen, P. B., Foo, S., Kostaras, E., Nathan, M. R., Wotherspoon, A., Gao, Z.-H., Shi, Y., et al. (2016) · Nature Medicine · doi:10.1038/nm.4197 · Cited by 454 · cited 1×
“in colorectal cancer liver metastases is associated with poor response to bevacizumab (38).”
BackgroundPD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines
Peng, W., Liu, C., Xu, C., Lou, Y., Chen, J., Yang, Y., Yagita, H., Overwijk, W. W., Lizée, G., Radvanyi, L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1187 · Cited by 432
Kloepper, J., Riedemann, L., Amoozgar, Z., Seano, G., Susek, K., Yu, V., Dalvie, N., Amelung, R. L., Datta, M., Song, J. W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525360113 · Cited by 357
Liang, W.-C., Wu, X., Peale, F. V., Lee, C. V., Meng, Y. G., Gutierrez, J., Fu, L., Malik, A. K., Gerber, H.-P., Ferrara, N., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508199200 · Cited by 346 · cited 1×
“Here, we show that a murinized mAb that efficiently blocks bothANGPT2 andVEGFA, termedA2V (12, 23), promotes antitumor immunity and sensitizes mouse tumors to PD-1 checkpoint blockade (24) better than single ANGPT2 or VEGFA neutralization by LC06 (13, 15) and B20 (25), respectively.”
BackgroundLund, A. W., Duraes, F. V., Hirosue, S., Raghavan, V. R., Nembrini, C., Thomas, S. N., Issa, A., Hugues, S., & Swartz, M. A. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.01.005 · Cited by 341
Targeting the tumor vasculature to enhance T cell activity
Lanitis, E., Irving, M., & Coukos, G. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.011 · Cited by 338 · cited 4×
“Blocking ANGPT2 prunes immature tumor blood vessels while promoting thematuration and stabilization of the remaining vessels (6–8, 14, 29); these vascular-normalizing effects may facilitate T cell trafficking in tumors (19, 20).”
BackgroundInfluentialPark, J.-S., Kim, I.-K., Han, S., Park, I., Kim, C., Bae, J., Oh, S. J., Lee, S., Kim, J. H., Woo, D.-C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.018 · Cited by 327
Dirkx, A. E. M., Egbrink, M. G. A. O., Kuijpers, M. J. E., van der Niet, S. T., Heijnen, V. V. T., Steege, J. C. A. B.-T., Wagstaff, J., & Griffioen, A. W. (2003) · PubMed · Cited by 325
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Osada, T., Chong, G., Tansik, R., Hong, T., Spector, N., Kumar, R., Hurwitz, H. I., Dev, I., Nixon, A. B., Lyerly, H. K., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0441-x · Cited by 311 · cited 1×
“The administration of bevacizumab to cancer patients increased the allostimulatory capacity and proliferation of DCs and T cells, respectively, in response to recall antigens ex vivo (48).”
BackgroundA critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells.
Qin, Z., Schwartzkopff, J., Pradera, F., Kammertoens, T., Seliger, B., Pircher, H., & Blankenstein, T. J. F. (2003) · PubMed · Cited by 288
Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
Hughes, P. E., Caenepeel, S., & Wu, L. C. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.04.010 · Cited by 282 · cited 1×
“Initial clinical data support the notion that inhibiting VEGFA signalingmay improve T cell–mediated antitumor immunity, particularly in association with immune checkpoint blockade (22, 46, 47).”
BackgroundBaer, C., Squadrito, M. L., Laoui, D., Thompson, D., Hansen, S. K., Kiialainen, A., Hoves, S., Ries, C. H., Ooi, C.-H., & De Palma, M. (2016) · Nature Cell Biology · doi:10.1038/ncb3371 · Cited by 259 · cited 4×
“RESULTS Combined ANGPT2 and VEGFA blockade provides marked survival benefits in both transgenic and transplant tumor models We studied tumor responses to combined or single ANGPT2 and VEGFA blockade in six mouse cancer models: (i) transgenic MMTVPyMTmice (FVB/nbackground),whichdevelopmetastatic breast cancer (6, 26);…”
BackgroundMethodInfluentialSelf-citationComplementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth
Hashizume, H., Falcón, B. L., Kuroda, T., Baluk, P., Coxon, A., Yu, D., Bready, J. V., Oliner, J. D., & McDonald, D. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1977 · Cited by 251
Angiopoietin‐2: a multifaceted cytokine that functions in both angiogenesis and inflammation
Scholz, A., Plate, K. H., & Reiss, Y. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12726 · Cited by 248
Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
Rigamonti, N., Kadioglu, E., Keklikoglou, I., Wyser Rmili, C., Leow, C. C., & De Palma, M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.059 · Cited by 247 · cited 5×
“LC06 decreased angiogenesis and delayed tumor growth in a transplanted MMTVPyMT tumor model, consistent with data obtained with a different anti-ANGPT2 antibody (6, 7).”
BackgroundResultInfluentialSelf-citationThe Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy
Miller, J. F. A. P., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.007 · Cited by 245 · cited 1×
“Cancer immunotherapies are treatments that restore or enhance the ability of the host immune system to recognize and eradicate cancer (16).”
BackgroundDaly, C., Eichten, A., Castanaro, C., Pasnikowski, E., Adler, A., Lalani, A. S., Papadopoulos, N., Kyle, A. H., Minchinton, A. I., Yancopoulos, G. D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2064 · Cited by 230
Coffelt, S. B., Chen, Y.-Y., Muthana, M., Welford, A. F., Tal, A. O., Scholz, A., Plate, K. H., Reiss, Y., Murdoch, C., De Palma, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002802 · Cited by 220
Effects of Angiopoietin-2-Blocking Antibody on Endothelial Cell–Cell Junctions and Lung Metastasis
Holopainen, T., Saharinen, P., D’Amico, G., Lampinen, A., Eklund, L., Sormunen, R., Anisimov, A., Zarkada, G., Lohela, M., Heloterä, H., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs009 · Cited by 216 · cited 1×
“Furthermore, ANGPT2 blockade markedly inhibits cancer metastasis via effects on both primary and metastatic tumors (6, 8, 15).”
BackgroundLiu, X.-D., Hoang, A., Zhou, L., Kalra, S., Yetil, A., Sun, M., Ding, Z., Zhang, X., Bai, S., German, P., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0244 · Cited by 204
Kienast, Y., Klein, C., Scheuer, W., Raemsch, R., Lorenzon, E., Bernicke, D., Herting, F., Yu, S., The, H. H., Martarello, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0081 · Cited by 201
Self-citationT L ymphocyte –E ndothelial C ell I nteractions
Choi, J., Enis, D. R., Koh, K. P., Shiao, S. L., & Pober, J. S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104639 · Cited by 195
McFadden, D. G., Politi, K., Bhutkar, A., Chen, F. K., Song, X., Pirun, M., Santiago, P. M., Kim-Kiselak, C., Platt, J. T., Lee, E., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613601113 · Cited by 194 · cited 1×
“The low mutational burden of genetically engineered mousemodels of cancer and some of the commonly usedmouse cancer cell lines may underlie their poor immunogenicity (62, 64).”
BackgroundDe Palma, M., & Hanahan, D. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.01.011 · Cited by 183
Nasarre, P., Thomas, M., Kruse, K., Helfrich, I., Wolter, V., Deppermann, C., Schadendorf, D., Thurston, G., Fiedler, U., & Augustin, H. G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3030 · Cited by 181
Scholz, A., Harter, P. N., Cremer, S., Yalcin, B. H., Gurnik, S., Yamaji, M., Di Tacchio, M., Sommer, K., Baumgarten, P., Bähr, O., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505505 · Cited by 169
Stagg, J., & Allard, B. (2013) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012475152 · Cited by 166
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
Wu, X., Giobbie-Hurder, A., Liao, X., Connelly, C., Connolly, E. M., Li, J., Manos, M. P., Lawrence, D., McDermott, D., Severgnini, M., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0206 · Cited by 164
Intertwined regulation of angiogenesis and immunity by myeloid cells
Rivera, L. B., & Bergers, G. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.005 · Cited by 158
Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy
Rivera, L. B., Meyronet, D., Hervieu, V., Frederick, M. J., Bergsland, E., & Bergers, G. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.055 · Cited by 147 · cited 1×
“In this regard, it was shown that blocking antiangiogenesis–induced immunosuppressionwith a PI3KG (phosphatidylinositol 3-kinase g) inhibitor translated into a better tumor control in mouse models of cancer (61).”
BackgroundSrivastava, K., Hu, J., Korn, C., Savant, S., Teichert, M., Kapel, S. S., Jugold, M., Besemfelder, E., Thomas, M., Pasparakis, M., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.11.005 · Cited by 140 · cited 2×
“Furthermore, ANGPT2 blockade markedly inhibits cancer metastasis via effects on both primary and metastatic tumors (6, 8, 15).”
BackgroundYamazaki, T., Akiba, H., Koyanagi, A., Azuma, M., Yagita, H., & Okumura, K. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1586 · Cited by 136 · cited 1×
“Here, we show that a murinized mAb that efficiently blocks bothANGPT2 andVEGFA, termedA2V (12, 23), promotes antitumor immunity and sensitizes mouse tumors to PD-1 checkpoint blockade (24) better than single ANGPT2 or VEGFA neutralization by LC06 (13, 15) and B20 (25), respectively.”
BackgroundChanging Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned
Santa-Maria, C. A., & Gradishar, W. J. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1198 · Cited by 126
Angiopoietin-2 promotes myeloid cell infiltration in a β2-integrin–dependent manner
Scholz, A., Lang, V., Henschler, R., Czabanka, M., Vajkoczy, P., Chavakis, E., Drynski, J., Harter, P. N., Mittelbronn, M., Dumont, D. J., et al. (2011) · Blood · doi:10.1182/blood-2011-03-343293 · Cited by 102
Active Immunotherapy Induces Antibody Responses That Target Tumor Angiogenesis
Schoenfeld, J., Jinushi, M., Nakazaki, Y., Wiener, D., Park, J., Soiffer, R., Neuberg, D., Mihm, M., Hodi, F. S., & Dranoff, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1852 · Cited by 77
Thomas, M., Kienast, Y., Scheuer, W., Bähner, M., Kaluza, K., Gassner, C., Herting, F., Brinkmann, U., Seeber, S., Kavlie, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054923 · Cited by 69 · cited 1×
“Here, we show that a murinized mAb that efficiently blocks bothANGPT2 andVEGFA, termedA2V (12, 23), promotes antitumor immunity and sensitizes mouse tumors to PD-1 checkpoint blockade (24) better than single ANGPT2 or VEGFA neutralization by LC06 (13, 15) and B20 (25), respectively.”
BackgroundSelf-citationMore than a scaffold: Stromal modulation of tumor immunity
Johansson, A., Hamzah, J., & Ganß, R. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.06.001 · Cited by 49
Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
Kuczynski, E. A., & Kerbel, R. S. (2016) · 癌症:英文版 · doi:10.1186/s40880-016-0162-7 · Cited by 27
Im, J. H., Tapmeier, T., Balathasan, L., Gal, A., Yameen, S., Hill, S., Smart, S., Noterdaeme, O., Kelly, M., Brady, M., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.27677 · Cited by 25 · cited 1×
“ANGPT2 neutralization might exacerbate vascular co-option by cancer cells (39), and there is also evidence that genetic Angpt2 deficiencymay aggravate the progression of colorectal liver metastasis in mice (40).”
BackgroundCancer Metastasis: Perivascular Macrophages Under Watch
Kadioglu, E., & Palma, M. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0819 · Cited by 20
Self-citationAntiangiogenic resistance via metabolic symbiosis
Jiménez-Valerio, G., & Casanovas, O. (2016) · Molecular & Cellular Oncology · doi:10.1080/23723556.2016.1211979 · Cited by 5
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
“Other studies have suggested that a dual anti-angiogenic approach with a bi-specific anti-VEGF/Ang2 antibody potentiated the activity of anti-PD-L1 treatment in multiple models (Schmittnaegel et al., 2017).”
BackgroundMacrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Microenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
“Interestingly, a dual inhibitor of VEGFA and ANG2 (A2V or vanucizumab) improved vessel normalization in preclinical models (228), which is being evaluated in clinical trials (229).”
Metadata
- Authors
- Schmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.-J., Ooi, C.-H., Laoui, D., & De Palma, M.
- Affiliations
- École Polytechnique Fédérale de Lausanne (CH)
- Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.
- F. Hoffmann-La Roche AG (CH)
- Roche Pharma AG (Germany) (DE)
- Corresponding author
- Schmittnaegel, Martina
- Rigamonti, Nicolò
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-04-12
- Volume
- 9
- Issue
- 385
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2606765235
- Cited by
- 582
- References
- 66
- Citations by year
- 2026: 37 · 2025: 53 · 2024: 55 · 2023: 65 · 2022: 77 · 2021: 75 · 2020: 77 · 2019: 57 · 2018: 56 · 2017: 28
- FWCI
- 26.45
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Leenaards Foundation
- Swiss Cancer League (KFS-3007-08-2012, KFS-3759-08-2015)
- San Salvatore Foundation
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- angiopoietin-2, VEGF-A, antitumor immunity, anti-PD-1 therapy, PD-L1, tumor endothelial cells, cytotoxic T lymphocytes, interferon-gamma, anti-angiogenic therapy, immune checkpoint blockade, cancer immunotherapy
- MeSH terms
- Animals, Blood Vessels, Mice, Inbred C57BL, Mice, Transgenic, CD8-Positive T-Lymphocytes, Vascular Endothelial Growth Factor A, Angiopoietin-2, Cell Line, Tumor, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.